secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001493152-23-039228
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell receives FDA clearance for Bria-OTS IND; reports preclinical data at SITC
--------------------------------------------------------------------------------

- FDA authorized Bria-OTS IND for clinical study of off-the-shelf personalized breast cancer immunotherapy.
- Preclinical data at SITC 2023 shows broad immune activation in tumor models by next-gen Bria-OTS+ and Bria-PROS+.
- Data indicates personalized HLA-matched platform covers >99% of US population with favorable safety profile.
- BriaCell expects to initiate clinical study of Bria-OTS and advance advanced versions for breast and prostate cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223039228/0001493152-23-039228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223039228/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer